Achilles Therapeutics Plc - ACHL STOCK NEWS

The global hospital infection therapeutics market is projected to grow by USD 3,106.6 million from 2022 to 2027, with a CAGR of 4.98%. The market is segmented by drug class (antibiotics, antifungals, antivirals) and infection type (respiratory, surgical, bloodstream, gastrointestinal, urinary). North America is expected to contribute 36% to this growth, driven by increasing chronic disease incidence and higher healthcare spending. Key market players include Abbott, Pfizer, and AstraZeneca, while challenges include stringent regulations affecting R&D.

Achilles Therapeutics (NASDAQ: ACHL) announced positive early proof-of-concept data for its cNeT therapy in heavily pre-treated advanced NSCLC patients, demonstrating sustained tumor reduction linked to clonal neoantigen targeting. As of December 31, 2022, the company reported a cash position of $173.3 million, sufficient to support operations into mid-2025. R&D expenses increased by $15 million to $57.3 million, reflecting intensified clinical trial activity. The net loss for 2022 was $71.2 million, or $1.82 per share. Looking ahead, the company aims to dose more patients and expand clinical data in NSCLC and melanoma.

Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, announced that Dr. Iraj Ali, CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 8:15 am PST in San Francisco. The conference will take place at the Westin St. Francis Hotel. A live and archived webcast of the presentation will be available on the company's website.

Achilles specializes in AI-powered precision T cell therapies targeting clonal neoantigens in cancer treatment, with ongoing Phase I/IIa trials for NSCLC and melanoma.

Achilles Therapeutics (ACHL) provided an interim update on its cNeT therapy for advanced NSCLC and melanoma at ESMO IO 2022. The data revealed durable clinical benefits with a confirmed partial response and stable disease in heavily pre-treated patients. Safety data indicates a favorable profile, potentially allowing treatment for patients ineligible for traditional therapies. The study included 14 patients, with a notable 71% of evaluable NSCLC patients showing clinical benefit. Further updates, including monotherapy and combination data, are anticipated in 2023.

Achilles Therapeutics announced promising interim results from the Phase I/II trials evaluating clonal neoantigen-reactive T cells (cNeT) for treating advanced non-small cell lung cancer (NSCLC). Durable partial responses and stable disease were observed in heavily pre-treated patients, suggesting potential for deep clinical responses. The trials demonstrated a favorable safety profile, with no dose-limiting toxicities. Findings will be presented at the ESMO Immuno-Oncology Congress from December 7-9, 2022, and a conference call is scheduled for December 6, 2022.

Achilles Therapeutics has received US patent 11,504,398 for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE). This patent covers various treatment modalities, including vaccines, antibodies, and autologous T cell therapies. The ACE method enhances the identification of patient-specific mutations, using data from the TRACERx study, aiming to improve precision in cancer treatments.

The patented technology employs advanced statistical frameworks to analyze mutations, potentially transforming cancer immunotherapy.

Achilles Therapeutics plc (NASDAQ: ACHL) reported its Q3 2022 financial results, announcing a net loss of $12.5 million, or $0.32 per share, slightly improved from $12.9 million, or $0.34 per share, in Q3 2021. The company has a cash balance of $179.9 million, expected to fund operations through Q2 2025, despite a net decrease of $45.7 million in cash flow due to operating activities and a $40.7 million foreign exchange impact. Updates from ongoing Phase I/IIa trials in NSCLC and melanoma will be presented at the ESMO Immuno-Oncology Congress in December.

Achilles Therapeutics plc (NASDAQ: ACHL) announces a virtual Neoantigen Expert Roundtable on October 13, 2022, at 12:30 PM ET featuring notable panelists, including Co-founder Charles Swanton and Dr. John Haanen. The discussion will focus on the significance of neoantigens in solid tumor therapies, covering neoantigen discovery and tumor-infiltrating lymphocyte (TIL) therapies. Moderated by Neil Canavan of LifeSci Partners, the event will include a live Q&A. Achilles is developing precision T cell therapies targeting clonal neoantigens specific to individual cancer patients.

Achilles Therapeutics plc (NASDAQ: ACHL) reported its Q2 2022 financial results, highlighting a cash balance of $202 million sufficient to fund operations through Q2 2025. The company is advancing its Phase I/IIa clinical trials for cNeT therapies targeting advanced non-small cell lung cancer (NSCLC) and melanoma, with further data expected in Q4 2022. Additionally, regulatory approval for its manufacturing facility enhances production capacity. R&D expenses rose to $14.8 million, while the net loss was $17.3 million or $0.44 per share, reflecting increased clinical activity.